摘要
目的 评价非细小细胞肺癌（NSCLC）患者术后人源核苷酸平衡转运体1（hENT1）蛋白表达水平与吉西他滨化疗敏感度的相关性。方法筛选2007—2011年浙江金华广福医院肿瘤内科收治的经病理确诊为NSCLC并行手术切除后患者47例，完全随机分为GP组和NP组，GP组23例选用吉西他滨联合顺铂化疗，顺铂80 mg/m^2，第 1-3 天静脉滴注，吉西他滨 800-1 250 mg/m^2，第1、8天使用；NP组24例选用长春瑞滨联合顺铂化疗，顺铂用法同前，长春瑞滨 25 mg/m^2，第1、8天使用。对47例患者手术切除肺癌组织蜡块标本采用免疫组织化学链霉菌抗生物素蛋白过氧化物酶连结法检测hENT1蛋白表达水平。术后实施2周期以上吉西他滨或长春瑞滨化疗，随访患者的生存期，评价hENT1蛋白表达水平与2种化疗方案疗效相关性。结果GP组hENT1高表达患者13例，无进展生存期为（28±18）个月，中位无进展生存期32个月；NP组hENT1高表达患者14例，无进展生存期为（24±16）个月，中位无进展生存期22个月，差异均有统计学意义（P=0.042，P=0.037）。GP组hENT1低表达患者（10例）中位总生存期35个月,NP组hENT1低表达患者（10例）中位总生存期34个月比较，差异无统计学意义（P＞0.05）。结论对于NSCLC患者， hENT1蛋白表达程度与吉西他滨的化疗敏感性相关。
ObjectiveTo evaluate the relevance between the gemcitabine chemotherapy sensitivity and the expression level of human equilibrative nucleoside transporter 1 （hENT1） after nonsmallcell carcinoma （NSCLC） operation. Methods A total of 47 NSCLC patients were divided into GP group （23 patients） and NP group （24 patients） by random digit grouping method. GP group received gemcitabine and cisplatin chemotherapy. Cisplatin was used intravenously at the dose of 80 mg/m^2 from the 1st to 3rd days and gemcitabine was used intravenously at the dose of 800 to 1 250 mg/m^2 on the 1st and 8th day. NP group received gemcitabine and cisplatin chemotherapy. Cisplatin was used intravenously as above and vinorelbine was used intravenously at the dose of 25 mg/m^2 on the 1st and 8th day. The expression level of hENT1 in lung cancer paraffin block specimens of the 47 NSCLC patients after operation was tested by immunohistochemical SP method; more than 2 cycles′ chemotherapy were implemented by Gemcitabine and vinorelbine. The patients′ life cycles were followed up and the relevance among gemcitabine chemotherapy sensitivity and the hENT1 expression level were evaluated. Resultsprogressionfree survival of hENT1 high expression was （28±18） months in GP group, （24±14） months in the NP group, the differences between the two groups was significant （P=0.042）, high expression median progressionfree survival was 32 months in the GP group ,and 22 months in the NP group, the difference between both groups was significant （P=0.037）. GP group had a median survival of 35 months after chemotherapy in the low expression of hENT1, while NP group had a median survival of 34 months after chemotherapy in the low expression of hENT1; the two groups had no significant difference （P〉0.05）. ConclusionsDegree of hENT1 expression associated with the chemosensitivity of gemcitabine. It may become a new target of gemcitabine chemotherapy for NSCLC.
出处
《中国医药》
2015年第2期165-169,共5页
China Medicine
基金
浙江省金华市科学技术研究计划项目（2011-3-076）
关键词
人源核苷酸平衡转运体1
非小细胞肺癌
晚期
吉西他滨
长春瑞滨
Human equilibrative nucleoside transporter 1
Non-small-cell carcinoma, advanced
Gemcitabine
Vinorelbine
